DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

CNC·Centene Corporation

$.
-. (-.%)
Pre-Market
High
$57.62
Open
$57.62
Market Cap
29.20B
52W High
$60.76
Low
$57.50
P. Close
$57.28
P/E
-
52W Low
$25.08
Fwd P/E
12.92
Mean Target
$58.06
Technical Score (1D)
86
BUY
News Sentiment
69
BULLISH
Barclays has increased its price target on Centene (CNC) to $75 from $63, while maintaining an 'Overweight' rating. This analyst action signals a more bullish outlook on the managed care provider's future prospects and potential for market outperformance. The adjustment suggests a positive view on Centene's strategic positioning and growth potential. Investors will be watching to see if this analyst conviction translates into sustained positive momentum for the stock.
Earnings Summary
Centene Corporation is a prominent healthcare services provider in the United States, specializing in managing health benefits for government-sponsored and commercially insured individuals across its Medicaid, Medicare, Commercial, and Other segments. Operating within the Healthcare sector, specifically the Healthcare Plans industry, Centene focuses on serving a broad population, including those with limited access to traditional healthcare, by offering comprehensive coverage and services. The company's business model is built on a network of providers to deliver essential medical, behavioral health, and pharmacy benefits. Centene's recent quarterly performance shows a mixed trend in earnings per share (EPS) against analyst estimates. In Q4 2025, the company reported an actual EPS of $0.50 against an estimate of -$0.16, a significant beat. This followed a miss in Q2 2025 where actual EPS was -$0.16 against an estimate of $0.21. Revenue trends have generally shown an upward trajectory, with Q4 2025 revenue at $49.73 billion, an increase from $49.69 billion in Q3 2025 and $48.74 billion in Q2 2025. The most recent quarter, Q1 2026, saw a strong EPS beat with actuals of $3.37 against an estimate of $2.13, accompanied by revenue of $49.94 billion. Historically, Centene has demonstrated a pattern of revenue growth, though EPS performance against estimates has been inconsistent. For instance, Q4 2025 revenue grew year-over-year, despite an EPS miss in the preceding quarter. The company has experienced both significant beats and misses relative to analyst expectations, indicating volatility in its earnings reporting. The beat in Q1 2026 EPS is a positive sign, following a pattern where revenue has often shown resilience even when EPS estimates were not met. Recent news highlights a divergence in analyst sentiment regarding Centene. UBS and BofA Securities have raised price targets, citing expectations of improving Medicaid margins and significant EPS upside potential from 2027 onwards. However, one analyst has flagged Centene as a stock to avoid due to concerns over core business underperformance and competitive market pressures. This mixed outlook suggests that while long-term margin improvement is anticipated, near-term execution on core business trends remains a key focus for investors. Looking ahead, investors will be watching for continued evidence of margin expansion and improvements in core business performance. Key will be Centene's ability to translate revenue growth into consistent EPS beats and to address concerns about organic revenue trends. The sustainability of the positive EPS surprise in Q1 2026 and any further shifts in analyst sentiment will be critical indicators for the company's upcoming performance.

EPS

EstBeatMiss
$-1.93$-0.43$1.07$2.56$4.06Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.05 - -
Q1'26$2.13$3.37+57.9%
Q4'25$-1.24$-1.19+3.7%
Q3'25$-0.16$0.50+404.3%
Q2'25$0.21$-0.16-177.3%
Q1'25$2.52$2.90+15.3%

Revenue

EstBeatMiss
$46.1B$47.2B$48.3B$49.4B$50.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$48.1B - -
Q1'26$47.6B$49.9B+5.0%
Q4'25$48.9B$49.7B+1.7%
Q3'25 - $49.7B -
Q2'25 - $48.7B -
Q1'25 - $46.6B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CNC Stock Snapshot

CNC is currently trading at $57.50, giving Centene Corporation a market cap of 29.20B. Today's range spans $57.50–$57.62, with shares opening at $57.62 and moving up $0.22 (0.4%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 69/100.

Over the past year CNC has traded between $25.08 and $60.76 - the current price is +129.3% off the 52-week low and -5.4% from the high. 27 analysts cover the stock with a Hold consensus and a mean 12-month target of $58.06 (range $40.00–$80.00), implying upside of +1.0%.

Centene Corporation (CNC) sits at $57.50 (near 52-week highs within $25.08–$60.76), scoring 86/100 (BUY) with bullish sentiment at 69/100. At 29.20B in Healthcare market cap, this large-cap is right in the zone where buy-side analysts get excited and allocation committees approve new position additions. A bullish technical phase with sentiment confirmation is the green light most of them are looking for.

The combination of a BUY signal (86/100) and bullish news sentiment (69/100) puts CNC on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 29.20B in Healthcare market cap without immediately moving the stock. At $57.50 (near 52-week highs in the $25.08–$60.76 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.